362 related articles for article (PubMed ID: 34874513)
1. Emerging immunological strategies: recent advances and future directions.
Zhao H; Luo F; Xue J; Li S; Xu RH
Front Med; 2021 Dec; 15(6):805-828. PubMed ID: 34874513
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy.
Rashidijahanabad Z; Huang X
Semin Immunol; 2020 Feb; 47():101390. PubMed ID: 31982247
[TBL] [Abstract][Full Text] [Related]
3. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
4. Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer.
Sivaganesh V; Promi N; Maher S; Peethambaran B
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33670942
[TBL] [Abstract][Full Text] [Related]
5. Cancer immune therapy for lymphoid malignancies: recent advances.
Klausen U; Jørgensen NGD; Grauslund JH; Holmström MO; Andersen MH
Semin Immunopathol; 2019 Jan; 41(1):111-124. PubMed ID: 30006739
[TBL] [Abstract][Full Text] [Related]
6. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
7. T Cell-Redirecting Strategies to 'STAb' Tumors: Beyond CARs and Bispecific Antibodies.
Blanco B; Compte M; Lykkemark S; Sanz L; Alvarez-Vallina L
Trends Immunol; 2019 Mar; 40(3):243-257. PubMed ID: 30827461
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Associated Glycans as Targets for Immunotherapy: The Wistar Institute Experience/Legacy.
Thurin M
Monoclon Antib Immunodiagn Immunother; 2021 Jun; 40(3):89-100. PubMed ID: 34161162
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy.
Yang P; Meng M; Zhou Q
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188558. PubMed ID: 33933558
[TBL] [Abstract][Full Text] [Related]
10. T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances.
Yu L; Wang J
J Cancer Res Clin Oncol; 2019 Apr; 145(4):941-956. PubMed ID: 30798356
[TBL] [Abstract][Full Text] [Related]
11. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.
Satta A; Mezzanzanica D; Turatti F; Canevari S; Figini M
Future Oncol; 2013 Apr; 9(4):527-39. PubMed ID: 23560375
[TBL] [Abstract][Full Text] [Related]
12. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
13. An overview of cancer immunotherapeutic strategies.
Wahid B; Ali A; Rafique S; Waqar M; Wasim M; Wahid K; Idrees M
Immunotherapy; 2018 Aug; 10(11):999-1010. PubMed ID: 30149763
[TBL] [Abstract][Full Text] [Related]
14. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!].
Riffard C; Teillaud JL
Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800
[TBL] [Abstract][Full Text] [Related]
15. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
16. Bringing Together the Power of T Cell Receptor Mimic and Bispecific Antibodies for Cancer Immunotherapy: Still a Long Way to Go.
Shivarov V; Blazhev G
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):81-85. PubMed ID: 33900820
[TBL] [Abstract][Full Text] [Related]
17. Using antibodies in tumour immunotherapy.
Schultes BC; Nicodemus CF
Expert Opin Biol Ther; 2004 Aug; 4(8):1265-84. PubMed ID: 15268661
[TBL] [Abstract][Full Text] [Related]
18. Engineering Immune Cells for
Blanco B; Ramírez-Fernández Á; Alvarez-Vallina L
Front Immunol; 2020; 11():1792. PubMed ID: 32903593
[TBL] [Abstract][Full Text] [Related]
19. Activated T cells armed with bispecific antibodies kill tumor targets.
Bhutani D; Lum LG
Curr Opin Hematol; 2015 Nov; 22(6):476-83. PubMed ID: 26457960
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal cancer stem cells as targets for innovative immunotherapy.
Chivu-Economescu M; Necula LG; Matei L; Dragu DL; Neagu AI; Alexiu I; Bleotu C; Diaconu CC
World J Gastroenterol; 2020 Apr; 26(14):1580-1593. PubMed ID: 32327907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
